Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | monoglyceride lipase | Starlite/ChEMBL | References |
Homo sapiens | fatty acid amide hydrolase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | esterase, putative | monoglyceride lipase | 303 aa | 254 aa | 19.7 % |
Leishmania major | hypothetical protein, conserved | fatty acid amide hydrolase | 579 aa | 471 aa | 26.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | fatty acid elongase, putative | 0.1031 | 0.1205 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0123 | 0.0049 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.1031 | 0.1205 | 1 |
Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.0084 | 0 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.1031 | 0.1205 | 1 |
Brugia malayi | amidase | 0.0123 | 0.0049 | 0.5 |
Schistosoma mansoni | amidase | 0.0123 | 0.0049 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.7939 | 1 | 1 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0123 | 0.0049 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.7939 | 1 | 1 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.7939 | 1 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.1031 | 0.1205 | 1 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0084 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.7939 | 1 | 0.5 |
Trypanosoma cruzi | monoglyceride lipase, putative | 0.0084 | 0 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.7939 | 1 | 1 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0084 | 0 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0084 | 0 | 0.5 |
Trypanosoma brucei | monoglyceride lipase, putative | 0.0084 | 0 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.7939 | 1 | 1 |
Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.0084 | 0 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0084 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0084 | 0 | 0.5 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0123 | 0.0049 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.7939 | 1 | 1 |
Schistosoma mansoni | fatty-acid amide hydrolase | 0.0123 | 0.0049 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0084 | 0 | 0.5 |
Leishmania major | monoglyceride lipase, putative | 0.0084 | 0 | 0.5 |
Echinococcus granulosus | fatty acid amide hydrolase 1 | 0.0123 | 0.0049 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.1031 | 0.1205 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0084 | 0 | 0.5 |
Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0084 | 0 | 0.5 |
Echinococcus multilocularis | fatty acid amide hydrolase 1 | 0.0123 | 0.0049 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 6.18 | Inhibition of human recombinant MAGL expressed in HEK293 cells using 2-AG as substrate | ChEMBL. | 25282655 |
IC50 (binding) | = 7.76 | Inhibition of human recombinant FAAH expressed in COS7 cells using anandamide as substrate | ChEMBL. | 25282655 |
IC50 (binding) | = 3.4 nM | Inhibition of human recombinant FAAH expressed in COS7 cells using anandamide as substrate | ChEMBL. | 25282655 |
IC50 (binding) | = 660 nM | Inhibition of human recombinant MAGL expressed in HEK293 cells using 2-AG as substrate | ChEMBL. | 25282655 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.